Biohaven's Exciting Year Of Catalysts

Group 1 - Biohaven, after its acquisition by Pfizer, has seen a significant increase in valuation, rising from an approximate $7 share price and a $300 million valuation [1] - The new venture led by Vlad Coric has demonstrated a steady growth trajectory in its market valuation [1] Group 2 - No additional relevant content available [2]